![Figure 2. Splenic expression of IL-33 is enhanced in FHL2 mice, and expression of ST2 is increased in mice and in patients with FHL2. Spleens and livers from Prf1−/− and WT mice were analyzed before and after LCMV infection. (A) Expression of Il33 at day 0 (Uninf) and at 7 days postinfection (Inf) (n = 4 mice per group). Analyzed by 2-way ANOVA. The number symbol indicates significance of genotype (WT vs Prf1−/−); the double dagger symbol indicates LCMV (Uninf vs Inf); and the asterisk indicates interaction between genotype and LCMV. ##P < .01; ‡‡‡P < .001; *P < .05. (B) Immunohistochemical staining of IL-33 in Prf1−/− mice. Original magnification ×200. Representative of 4 mice per group. (C) IL-33 immunohistochemistry in livers of LCMV-infected Prf1−/− mice 8 days p.i., with or without in vivo administration of ST2-blocking antibody. Representative of 4 mice per group. Original magnification as indicated. (D) Expression of Il1rl1 (ST2 gene), analyzed as in panel A; *P < .05; ‡‡‡P < .001; #P < .05; **P < .01; ##P < .01. (E) Expression of IL1RL1 in peripheral blood mononuclear cells from pediatric patients with FHL2 (n = 3), patients with systemic juvenile idiopathic arthritis (sJIA, n = 18), and healthy control subjects (control 1, n = 33; control 2, n = 29). Data are combined from 2 published data sets (GSE26050 [triangles] and GSE21521 [diamonds]).20,21 Analyzed by 1-way ANOVA; ***P < .001 by Dunnett multiple comparison posttest comparing FHL2 patients to all other groups. ANOVA, analysis of variance; AU, arbitrary units; mRNA, messenger RNA; p.i., postinfection.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/127/4/10.1182_blood-2015-07-659813/4/426f2.jpeg?Expires=1726826720&Signature=oQiUudcwn9PwNWIK~Swfp~YjKw45jCaZmevFOl-h0VcTsgs8fjaRwyzwtR8wii5WJNknH6di-Z1RfiTMsTlanVYNAPQKFahp3DES5wrN0UpBOcO4Rc44Uv~oSeFoiZdUvn37CIRdyzepa8JM45E5hJ~aJ88eiawW4ntJF2~67EkSDNjLRATW77~Gdrr5NrPkawmxaDJSltQeO5NLT1kDJzAtxgfmqvRyRHOaqQJpggMZk1YtEG6U8-ZZfBmJSoCT6YnRSzJ2xXz-BdUYqu3gSYgBTSZS-I6dFlJlxaDB~UGYrljgSLcrSYFD7EvqjL-jRx8IrJVDvLTK5fSmU6EirA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Splenic expression of IL-33 is enhanced in FHL2 mice, and expression of ST2 is increased in mice and in patients with FHL2. Spleens and livers from Prf1−/− and WT mice were analyzed before and after LCMV infection. (A) Expression of Il33 at day 0 (Uninf) and at 7 days postinfection (Inf) (n = 4 mice per group). Analyzed by 2-way ANOVA. The number symbol indicates significance of genotype (WT vs Prf1−/−); the double dagger symbol indicates LCMV (Uninf vs Inf); and the asterisk indicates interaction between genotype and LCMV. ##P < .01; ‡‡‡P < .001; *P < .05. (B) Immunohistochemical staining of IL-33 in Prf1−/− mice. Original magnification ×200. Representative of 4 mice per group. (C) IL-33 immunohistochemistry in livers of LCMV-infected Prf1−/− mice 8 days p.i., with or without in vivo administration of ST2-blocking antibody. Representative of 4 mice per group. Original magnification as indicated. (D) Expression of Il1rl1 (ST2 gene), analyzed as in panel A; *P < .05; ‡‡‡P < .001; #P < .05; **P < .01; ##P < .01. (E) Expression of IL1RL1 in peripheral blood mononuclear cells from pediatric patients with FHL2 (n = 3), patients with systemic juvenile idiopathic arthritis (sJIA, n = 18), and healthy control subjects (control 1, n = 33; control 2, n = 29). Data are combined from 2 published data sets (GSE26050 [triangles] and GSE21521 [diamonds]).20,21 Analyzed by 1-way ANOVA; ***P < .001 by Dunnett multiple comparison posttest comparing FHL2 patients to all other groups. ANOVA, analysis of variance; AU, arbitrary units; mRNA, messenger RNA; p.i., postinfection.
